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Induced CNS expression of CXCL1 augments neurologic
disease in a murine model of multiple sclerosis via
enhanced neutrophil recruitment
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and Thomas E. Lane1,2
1 Department of Pathology, Division of Microbiology and Immunology, University of Utah,
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Increasing evidence points to an important role for neutrophils in participating in the
pathogenesis of the human demyelinating disease MS and the animal model EAE. There-
fore, a better understanding of the signals controlling migration of neutrophils as well
as evaluating the role of these cells in demyelination is important to define cellular com-
ponents that contribute to disease in MS patients. In this study, we examined the func-
tional role of the chemokine CXCL1 in contributing to neuroinflammation and demyeli-
nation in EAE. Using transgenic mice in which expression of CXCL1 is under the control
of a tetracycline-inducible promoter active within glial fibrillary acidic protein-positive
cells, we have shown that sustained CXCL1 expression within the CNS increased the
severity of clinical and histologic disease that was independent of an increase in the
frequency of encephalitogenic Th1 and Th17 cells. Rather, disease was associated with
enhanced recruitment of CD11b+Ly6G+ neutrophils into the spinal cord. Targeting neu-
trophils resulted in a reduction in demyelination arguing for a role for these cells inmyelin
damage. Collectively, these findings emphasize that CXCL1-mediated attraction of neu-
trophils into the CNS augments demyelination suggesting that this signaling pathway
may offer new targets for therapeutic intervention.
Keywords: Autoimmunity  Chemokines  Demyelination  Neuroinflammation  Neutrophils
 Additional supporting information may be found in the online version of this article at thepublisher’s web-site
Introduction
EAE is a T cell-driven autoimmune disease sharing many clini-
cal and pathologic features with the human demyelinating dis-
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ease MS [1–3]. In EAE, CD4+ and CD8+ T-cells specific for self-
antigens expressed in CNSmyelin initiate a localized inflammatory
process that results in demyelination, axonopathy, and clinical
deficits [4–6]. The concept that the adaptive immune response
is critical for new lesion development and disease progression
in MS is emphasized in that FDA-approved disease modifying
therapies are designed to limit infiltration of encephalitogenic
C© 2018 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co.
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lymphocytes into the CNS [7]. Among the mechanisms by which
myelin-reactive CD4+ T-cells contribute to disease is through
localized secretion of cytokines, e.g. IL-17 that increases expres-
sion of chemokines that attract myeloid cells into the CNS
[8]. Monocytes and macrophages amplify white matter damage
through active stripping of the myelin sheath leading to axonal
damage, presentation of novel myelin epitopes to T cells and
amplifying neuroinflammation through secretion of proinflam-
matory molecules. In addition, IL-17 secretion increases expres-
sion of the neutrophil chemoattractants CXCL1 and CXCL2 result-
ing in recruitment and accumulation of these cells within the
CNS [9].
Increasing evidence in both preclinical models of MS as
well as from MS patients have highlighted a potentially impor-
tant role for neutrophils in demyelination [10–20]. Neutrophil
depletion delays the onset of clinical symptoms in EAE mice
arguing for a role for these cells in disease initiation and/or
lesion formation [9, 13, 17, 19]. Studies designed to decipher
the mechanisms by which neutrophils augment disease pro-
gression point to increases in vascular permeability as well as
secretion of reactive nitrogen and oxygen species [14, 18]. In
patients with relapsing-remitting MS, there are elevated sys-
temic levels of neutrophil-activating chemokines including CXCL1,
CXCL5, and neutrophil elastase accompanied by increased num-
bers of neutrophils having a primed phenotype [10, 12]. Col-
lectively, these findings from preclinical models as well as MS
patients argue for a role for neutrophils in contributing to
disease.
Given the transient nature of neutrophils in terms of having a
short half-life, limited presence within lesions, and tightly regu-
lated expression of chemotactic signals underscores the challeng-
ing aspects involved in understanding the role of these cells in
autoimmune demyelination. To overcome some of these limita-
tions, we have derived a transgenic mouse whereby expression of
CXCL1 is under the control of a tetracycline-inducible promoter
that is active within glial fibrillary acidic protein (GFAP)-positive
astrocytes [21]. Recent studies have emphasized an important
role for CXCL1 and it is receptor CXCR2 during the effector phase
of EAE [9, 22–24]. Although resident cells of the CNS including
microglia and endothelial cells express CXCL1 [24, 25], astrocytes
have been shown to express CXCL1 in EAE as well as in MS lesions
[26–28] and this informed our decision to select astrocytes as our
target cell for ectopic expression of CXCL1. Our present study was
undertaken to better understand how elevated and sustained neu-
trophil recruitment into the CNS impacts EAE disease progression
and white matter damage. Our findings indicate that increased
expression of CXCL1 within the CNS results in more severe EAE as
measured by both clinical disease and demyelination. The CXCL1-
mediated disease enhancement was not dependent on an increase
in myelin-reactive Th1 or Th17 cells but correlated with increased
numbers of neutrophil infiltration into the spinal cord. Indeed,
depletion of neutrophils resulted in a reduction in the severity
of white matter damage highlighting a role for these cells in
demyelination.
Results
Increased clinical disease following Dox-induced
expression of CXCL1
Following induction of EAE, CD4+ T-cell-derived IL-17 expression
in the CNS potentiates disease by enhancing expression of the
neutrophil chemoattractants CXCL1 and CXCL2 [9]. The accumu-
lation of neutrophils in the CNS is rapid yet transient and reflects
the expression kinetics of CXCL1 and CXCL2. To better under-
stand how neutrophil infiltration impacts demyelination and dis-
ease progression in EAE, transgenic (tg) mice were engineered
to express CXCL1 within GFAP-positive astrocytes upon doxycy-
cline administration, as previous studies have shown these cells to
be the primary source of CXCL1 in models of neuroinflammation
[29, 30]. Doxycyline (Dox) responsive double tgmice (pBI-CXCL1-
rtTA) or single tg controls lacking the reverse tetracycline transac-
tivator (rtTA) were immunized withMOG35–55 peptide and treated
daily with Dox (50 mg/kg) i.p. between days 9 through 19 postim-
munization (Fig. 1A). Onset of clinical diseasewas similar between
Dox-treated double tg and single tg mice (day 9 p.i.), but double
tg mice exhibited a significant increase in clinical disease sever-
ity compared to single tg mice (Fig. 1B). Examination of mRNA
transcripts encoding proinflammatory chemokines/cytokines indi-
cated a selective >twofold increase in CXCL1 in Dox-treated dou-
ble tg mice versus single tg mice at day 12 postimmunization that
represents a time in which there is a separation in clinical disease
between double and single tg mice following MOG35–55 immuniza-
tion. No differences in expression of transcripts encoding CXCL2,
CXCL10, CCL2, CCL5, IFN-γ, and IL-17A at day 12 between Dox-
treated double tg and single tg mice were observed (Fig. 1C). A
significant (p< 0.05) increase in CXCL1 protein was detected only
in the spinal cord (Fig. 1E) and not in the serum (Fig. 1D) of double
tg mice 12 days postimmunization compared to single tg controls.
Notably, we also observed a significant (p < 0.05) increase in
CXCL1 protein within the spinal cords of Dox-treated na¨ıve mice
in which EAE was not induced indicating that disease induction
did not selectively enhance transgene expression (Fig. 1E). We
did not detect differences in proteins levels of G-CSF, GM-CSF, or
IL-17 (data not shown) either prior to or following Dox treatment
of double tg or single tg EAE mice. Immunofluorescence staining
confirmed astrocytes (GFAP+) as the primary cellular source of
CXCL1 in Dox-treated double tg EAE mice (Fig. 1F). Together,
these findings indicate that CXCL1 expression was specifically ele-
vated in the CNS of Dox-treated double tg mice that correlated
with an increase in clinical disease.
Induced expression of CXCL1 does not increase either
T cell or macrophage infiltration into the CNS
MOG35–55-induced EAE disease correlates with CNS infiltration
of Th1 and Th17 CD4+ T-cells reactive against the encephali-
togenic MOG peptide [31]. In addition, other immune subsets
C© 2018 The Authors. European Journal of Immunology published by
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Figure 1. Dox-inducedCXCL1 expression increases clinical disease severity followingMOG35–55-induced EAE. (A) Schematic outline of experimental
approach for disease induction and Dox administration. MOG, MOG35–55 peptide; PTX, pertussis toxin. (B) Clinical disease score was measured in
MOG35–55-immunized double tg mice (n = 26) compared to single tg (n = 29) following Dox treatment. Data were pooled from four independent
experiments with between 6–8 mice per experiment. (C) mRNA transcripts of Cxcl1 and other pro-inflammatory cytokines/chemokines in Dox-
treated double tg mice (n = 2) compared to single tg mice (n = 2) at day 12 p.i; data presented is representative of two independent experiments
with a total of four mice per experimental group. CXCL1 levels in serum (D) and spinal cords (E) of MOG35–55-immunized mice was determined
by ELISA’s at day 12 postimmunization. CXCL1 expression in spinal cords of either Dox- or vehicle-treated double tg mice in the absence of
peptide immunization (naı¨ve) was also determined 3 days following last Dox injection (E); data is pooled from two independent experiments with
between 2–4 mice for each experiment. (F) Representative immunofluorescence staining (60X) showing colocalization of CXCL1 protein (green)
with GFAP-positive (red) astrocytes in double tg mice at day 12 following Dox treatment (scale bar = 5 μm). Statistical analysis employed unpaired
two-tailed Student’s t test; data presented as average ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
including CD8+ T cells, B cells, and macrophages are also consid-
ered important in amplifying clinical disease and pathology [31].
We determined if overexpression of CXCL1 in the CNS of Dox-
treated double tg mice immunized with MOG35–55 peptide altered
the infiltration of inflammatory leukocytes into the CNS. We did
not detect differences in the frequency or numbers of CD45hi
leukocytes (data not shown), CD4+ T cells (Fig. 2A and B), or
CD8+ T cells (Fig. 2C and D) in spinal cords of Dox-treated dou-
ble tg mice compared to single tg mice. Moreover, there was
no difference in intracellular CD4+ T-cell cytokine expression
of IFN-γ, IL-17A, or coexpressing IFN-γ and IL-17A within the
spinal cords at day 12 p.i. following PMA/ionomycin stimulation
(Fig. 2E and F). We did not observe changes in macrophages
(CD45hiF4/80+) (Fig. 3A), microglia (CD45loF4/80+) (Fig. 3B),
or macrophages or microglia coexpressing MHC class II and CD80
(Fig. 3C and D) of Dox-treated double and single tg EAE mice. Col-
lectively, these findings argue that the increase in clinical disease
following Dox-induced CXCL1 expression within the CNS is not
due to increased infiltration of myelin-reactive CD4+ T cells nor
other immune cells that are known to contribute to EAE disease
severity.
Increased neutrophil accumulation in response to
Dox-induced expression of CXCL1
CXCL1 is a potent chemoattractant of neutrophils expressing
the chemokine receptor CXCR2 and its overexpression from
C© 2018 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 2. T-cell infiltration into the CNS is not altered following Dox-induced expression of CXCL1. Spinal cords were removed at day 12 following
MOG35–55 immunization of Dox-treated double tg (n = 10) and single tg (n = 10) mice and the presence of CD45+CD4+ T cells (A, B) or CD45+CD8a+
T cells (C, D) determined by flowcytometry. The gating scheme employed is depicted in Supporting Information Fig. S1. Representative contour blots
from experimental animals are shown in panels A and C. Data in panels B and D are pooled from two independent experiments with aminimum of
three mice per experimental group; data is presented as mean ± SEM. (E and F) Expression of cytokines IL-17A and/or IFN-γ in Dox-treated double
tg or single tg following PMA/ionomycin treatment of CD4+ T-cells isolated from spinal cords at day 12 following MOG35–55 immunization. Data in
panel E are representative contour plots showing the results of intracellular staining for IL-17A and IFN-γ following PMA/ionomycin treatment of
CD4+ T cells. The gating scheme employed is depicted in Supporting Information Fig. S2. Data in panel F represent quantification of intracellular
cytokine staining and pooled from three independent experiments with a minimum of two mice per experimental group and presented as mean
± SEM and statistical analysis employed unpaired two-tailed Student’s t test.
astrocytes enhances the migration and accumulation of neu-
trophils in the white matter tracts of the spinal cords in a model
of viral-induced encephalomyelitis [21, 32]. We next investi-
gated whether Dox-induced overexpression of CXCL1 promotes
neutrophil accumulation in double tg mice induced with EAE.
Histopathologic examination of spinal cord sections revealed
increased localization of inflammatory cells in the anterior median
fissure and meninges of the spinal cords of Dox-treated double tg
mice compared to single tg EAE mice (Fig. 4A). The majority of
inflammatory cells within spinal cords of double tgmice had amul-
tilobed nucleus characteristic of neutrophils (Fig. 4B). Immunoflu-
orescence staining revealed increased numbers of cells positive for
the neutrophil-associated surface antigen Ly6B.2 within the spinal
cords of Dox-treated double tg EAE mice compared to single tg
mice treated with Dox (Fig. 4C). In addition, flow analysis of spinal
cords isolated from experimental mice indicated the frequency and
numbers of neutrophils (CD45hiCD11b+Ly6G+) within the spinal
cords of Dox-treated double tg mice were significantly (p < 0.01)
increased compared to single tg mice (Fig. 4D and E). Importantly,
we did not observe an increase in Ly6C+ monocytes in either
brain or spinal cords of double tg mice treated with Dox (data
not shown). Together, these findings argue that the Dox-induced
increase in CXCL1 expression within the CNS enhances the recruit-
ment and accumulation of neutrophils within the spinal cords
associated increased clinical disease severity. Using a model of
viral-induced demyelination, we have previously shown that Dox-
induced CXCL1 expression within the CNS increases the severity of
white matter damage and this was correlated with enhanced neu-
trophil recruitment into the spinal cord [21]. Assessment of spinal
cord pathology between Dox-treated single tg and double tg mice
was assessed using H&E/LFB staining at day 21 p.i. (Fig. 4F). We
recorded an increase in both meningeal infiltration (p< 0.05) and
demyelination (p < 0.05) of double tg compared to single tg was
observed (Fig. 4G).
C© 2018 The Authors. European Journal of Immunology published by
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Figure 3. Dox-induced CXCL1 within the CNS does
not increase microglia/macrophage activation. Dox-
treated double and single tg mice were sacrificed at
day 12 following MOG35–55 immunization and spinal
cords removed to assess macrophage (CD45hi F4/80+)
(A) andmicroglia (CD45loF4/80+) (B) activation via flow
cytometric staining between double tg (n = 10) or sin-
gle tg (n = 10) mice. The gating scheme employed
is depicted in Supporting Information Fig. S3. Sur-
face expression of activation markers MHC class II
and CD80 was also examined on macrophages (C) or
microglia (D) between double tg (n = 7) and single
tg (n = 7) mice. Data in panels A and B were pooled
from three independent experiments; data in pan-
els C and D from two independent experiments. Data
are presented as mean ± SEM and statistical analysis
employed unpaired two-tailed Student’s t test.
C© 2018 The Authors. European Journal of Immunology published by
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Figure 4. Neutrophil infiltration into the CNS is associated with increased demyelination. MOG35–55-immunized double and single tg mice treated
with Dox were sacrificed at day 12 postimmunization and spinal cords removed to assess histopathology and myeloid cell infiltration. (A)
Representative H&E/Luxol fast blue staining of the spinal cords of experimental mice revealed increased inflammation within the anterior median
fissure of double tg mice compared to single tg mice, 20X magnification. (B) Representative image of a spinal cord of Dox-treated double tg mouse
showing cells with multilobed nuclei (red arrows) characteristic of neutrophils, 60X magnification. (C) Representative immunofluorescent staining
for the neutrophil-specific surface antigen Ly6B.2 of double tg mice compared to single tg mice, 20Xmagnification. (D) Representative contour flow
graphs showing increase in neutrophils (CD45hi CD11b+ Ly6G+) within the spinal cords of double tg mice compared to single tg mice. The gating
scheme employed is depicted in Supporting Information Fig. S4. (E) Quantification of neutrophil flow staining in the spinal cords of double tg mice
(n = 10) compared to single tg mice (n = 10). Data in panel E were derived from three independent experiments and data presented as mean
± SEM. (F) Representative H&E/LFB stained spinal cord images (4X) demonstrated increased demyelination (outlined in black) in double tg mice
compared to single tg mice at day 21 p.i. (G) Quantification of neuropathology indicated increased meningeal inflammation (p < 0.05), perivascular
cuffing and demyelination (p < 0.05) at score at day 21 p.i. in double tg mice (n = 9) compared to single tg mice (n = 9); data pooled from three
independent experiments. Statistical analysis employed unpaired two-tailed Student’s t test, **p < 0.01.
C© 2018 The Authors. European Journal of Immunology published by
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Figure 5. Targeting neutrophils diminishes the severity of demyelination. MOG35–55-immunized double and single tg mice treated with Dox were
sacrificed at day 21 postimmunization and spinal cords removed to assess histopathology and myeloid cell infiltration. (A) Schematic outline for
experimental design to target neutrophils in Dox-treated double tg mice via injection of either anti-CXCR2 or NRS control antibody. (B) Treatment
with anti-CXCR2 in Dox-treated double tg mice (n = 7) compared to animals treated with NRS (n = 9); data pooled from three independent
experiments with 2–3 mice per experiment. (C) Anti-CXCR2 treatment in Dox-treated double tg mice (n = 3) resulted in reduced (p < 0.01) levels
of neutrophils (CD45hi CD11b+ Ly6C+ Ly6G+) in blood compared to NRS-treated mice (n = 3); data derived from two independent experiments
presented asmean± SEM. The gating scheme employed is depicted in Supporting Information Fig. S5. (D) Representative H&E/LFB images depicting
a reduction in demyelination (outlined in black) in Dox-treated double tg compared to single tg mice and (E) quantification showed a significant
(p < 0.01) reduction in demyelination in anti-CXCR2 treated mice (n = 6) compared to NRS-treated mice (n = 4); data is representative of two
independent experiments. (F) Representative immunofluorescent staining for neutrophils (Ly6B.2) reveals fewer positive cells within the spinal
cords of anti-CXCR2-treated mice compared to NRS-treated mice. (G) Quantification of spinal cord Ly6B.2-positive neutrophils reveals reduced
numbers in anti-CXCR2-treated mice (n = 3) compared to NRS-treated mice (n = 3); data derived from two independent experiments presented
as mean ± SEM. **p < 0.01, ***p < 0.001.
Neutrophils increase the severity of demyelination in
Dox-treated double tg EAE mice
In order to determinewhether neutrophils contributed to enhance-
ment of demyelination, MOG35–55-immunized double tg mice
treated with Dox were administered anti-CXCR2 antisera which
we have previously shown to effectively target neutrophils [30,
32]. Anti-CXCR2 or NRS was administered to Dox-treated dou-
ble tg mice at defined times following EAE induction (Fig. 5A).
Administration of anti-CXCR2 antisera to Dox-treated double tg
C© 2018 The Authors. European Journal of Immunology published by
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mice resulted in a dramatic reduction in clinical disease sever-
ity compared to animals treated with NRS alone (Fig. 5B)
and this was correlated with reduced numbers of circulating
CD45hiCD11b+Ly6C+Ly6G+ neutrophils (Fig. 5C). The reduction
in clinical disease in Dox-treated double tg mice treated with anti-
CXCR2 correlated with a significant (p < 0.01) reduction in the
severity of demyelination compared to NRS-treated mice (Fig. 5D
and E) and this was associated with reduced numbers of neu-
trophils present within the spinal cords (Fig. 5F and G). Together,
these findings indicate that neutrophils can enhance the severity
of demyelination in MOG35–55-induced EAE.
Discussion
MS is characterized by CNS inflammatory lesions consisting of
activated lymphocytes and monocyte/macrophages that are asso-
ciated with demyelinating lesions within the brain and spinal cord
[24, 33]. The importance of these cells to disease is highlighted in
that FDA-approved disease modifying therapies used in treatment
of relapsing remitting MS limit immune cell infiltration and lesion
development [34, 35]. Nonetheless, there is increasing interest
in the potential role of other cell types, including neutrophils,
in participating in demyelination. The diverse functions of neu-
trophils include phagocytosis, release of toxic granules, and secre-
tion of ROS, nitrogen species, and neutrophil extracellular traps
that can lead to bacterial clearance and tissue damage [36–39]. In
addition, neutrophils can produce many different cytokines and
chemokines that participate in tailoring the immune response as
well as enhancing neuroinflammation [36–39]. Although there is
direct evidence that neutrophils are important in both disease ini-
tiation and progression in EAEmodels only indirect evidence exists
showing these cells also play a role in MS pathogenesis [40]. Since
neutrophils are typically short-lived and have a half-life in circu-
lation (between 6 and 8 hours in humans) [41], direct evidence
of neutrophils in MS lesions from available autopsy tissue samples
has been limited. Nonetheless, recent studies from Segal and col-
leagues [12] have demonstrated increased systemic levels of the
chemokines CXCL1 and CXCL5 as well as neutrophil elastase that
correlated with lesion burden and clinical disability in MS patients
arguing for a role for neutrophils in augmenting disease.
The current study was performed to better understand the
functional role of CXCL1 within the CNS following induction of
MOG35–55 immunized EAE in mice. CXCL1 is a member of the
ELR (+) family of CXC chemokines and binds with high affinity
to the chemokine receptor CXCR2 [11, 42]. Neutrophils express
CXCR2 and signaling enhances egress out of the BM and aids
in homing to sites of inflammation [36]. In the context of EAE,
CXCL1 is detected early in the CNS [24] both prior to and fol-
lowing disease onset [12]. Mice treated with anti-CXCL1 blocking
antibody showed a delayed onset of disease and decreased clin-
ical disease correlating with diminished numbers of Ly6G+ neu-
trophils yet CNS T-cell infiltration was not affected arguing for
a role for neutrophils in disease [24]. Similarly, a better under-
standing of molecules, e.g. CXCL1 that influence neutrophil accu-
mulation within the CNS also allows insight into the therapeutic
relevance of these potential targets. Lira et al. [43] have previ-
ously shown that transgenic mice in which CXCL1 was constitu-
tively expressed from oligodendrocytes led to the development of
neurologic disease associated with microglia and astrocyte reactiv-
ity that correlated with increase in neutrophil accumulation within
the brain. Using the animals described in this study in which trans-
genic Cxcl1 is selectively expressed in astrocytes upon Doxycy-
cline treatment, we recently showed that increased and sustained
expression of CXCL1 was associated with increased clinical disease
and demyelination in animals infected with the neurotropic JHM
strain of mouse hepatitis virus (JHMV) [21]. Enhanced clinical
and histologic disease correlated with a dramatic increase in neu-
trophil infiltration into the CNS; targeted ablation of neutrophils
resulted in a reduction in the severity of demyelination further
supporting an important role for neutrophils in augmenting white
matter damage [21].
Using this transgenic mouse in which CXCL1 expression is
selectively induced within astrocytes allows for an increased
understanding of how neutrophils may augment neuroinflamma-
tion and demyelination in EAE. Similar to our previous report
using JHMV infection of CXCL1 double transgenic mice [21],
we found that Dox administration resulted in elevated CXCL1
transgene expression within the brains and spinal cords of dou-
ble tg mice that was restricted to astrocytes and correlated with
rapid and robust neutrophil migration to the CNS compared to
Dox-treated controls. As a result of CXCL1 transgene expression,
MOG35–55-immunized double tg mice displayed sustained increase
in clinical disease severity. Increased accumulation of neutrophils
in the CNS did not affect the expression of proinflammatory fac-
tors that could potentially attract inflammatory leukocytes and/or
increase numbers of resident glial cells. Indeed, we observed no
statistical difference in the frequencies or numbers of either acti-
vatedmacrophages or microglia expressingMHC class II and CD80
between Dox-treated double tg and single tg mice. Furthermore,
we did not detect any increase in either frequency or numbers
of CNS inflammatory CD4+ or CD8+ T cells in Dox-treated dou-
ble tg mice compared to Dox-treated single tg mice. In addi-
tion, there were no differences in the expression of IFN-γ and/or
IL-17A by CD4+ T-cells between Dox-treated double and single
tg mice. Collectively, these findings indicate that the increase
in MOG35–55-induced clinical disease upon Dox-induced CXCL1
expression is not the result of increased infiltration/activation of
either macrophages/microglia or T cells. Of additional interest
is our observation that Dox-treatment of na¨ıve double tg mice
resulted in increased expression of CXCL1 within the CNS and
these findings argue that induction of EAE is dispensable in terms
increased expression of this transgene. Ongoing studies in our lab-
oratory are determining if sustained CXCL1 expression within the
CNS is sufficient to contribute to demyelination mediated by neu-
trophil accumulation in the absence of MOG35–55 immunization.
In contrast with our findings, Omari et al. [44] demon-
strated that overexpression of CXCL1 by astrocytes protected
animals from EAE by limiting neuroinflammation as well as
increasing numbers of oligodendrocytes associated with enhanced
C© 2018 The Authors. European Journal of Immunology published by
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remyelination. This difference in results most likely reflects that
the Cxcl1 transgene employed in our study was lacking the 3’ UTR
resulting in an increase in the half-life of CXCL1 mRNA and there-
fore sustained CXCL1 production and subsequently neutrophil
accumulation whereas Omari et al. was using a transgene con-
taining the 3’UTR and nonsustained expression of CXCL1 [44].
We do not believe CXCL1 had any direct cytotoxic activity on
oligodendroglia as we have previous shown that treatment of dif-
ferentiating mouse oligodendrocyte progenitor cells with recom-
binant CXCL1 does not kill these cells [45]. Rather, our findings
argue that increased white matter damage is associated with a
selective increase in neutrophil accumulation within the CNS and
this is consistent with earlier studies from our laboratory using
the CXCL1 transgenic animals in a model of viral-induced neuro-
logic disease [21]. Although recent studies suggest that Ly-6C+
myeloid precursor cells play a pathogenic role during autoimmune
demyelination [46], our findings reveal that the increase in tissue
damage was not the result of enhanced migration of these cells
to the CNS of Dox-treated double tg mice when compared to sin-
gle tg mice. Molecules that neutrophils are known to possess that
potentially could impact cell survival include neutrophil elastase,
cathepsin G, and matrix metalloproteinases [39]. Indeed, neu-
trophils have clearly been shown to exacerbate brain injury in a
model of focal cerebral ischemia [47]. Blocking neutrophil traf-
ficking to the CNS or inhibition of the NAPDH complex in mouse
models of ischemic injury results in a dramatic reduction in both
the vascular endothelium and brain parenchyma [47, 48]. More-
over, both the generation of ROS and nitric oxide is thought to
contribute to vascular damage as well as impact axonal integrity
and oligodendrocyte viability [49, 50]. Neutrophils are also impli-
cated in exacerbating lesion development within spinal cords on
patients with neuromyelitis optica (NMO) [51], and inhibition of
neutrophil elastase, a serine protease released from the primary
granules of neutrophils, within mouse models of NMO resulted
in reduced neuroinflammation and myelin loss [52, 53]. Within
the EAE model of chronic neurologic disease, neutrophils have
recently been reported to have a role in maturating local APCs
within the CNS thus potentially contributing to increased dis-
ease severity by increasing numbers of autoreactive T cells [54].
However, we believe it unlikely that the increase in disease
severity is the result of enhanced macrophages presenting anti-
gen as we determined there was no increase in either activated
macrophage or microglia in the CNS of Dox-treated double tg mice
nor were there increases in either Th1 and/or Th17 CD4+ T-cell
responses.
The importance of neutrophils in enhancing white matter dam-
age in Dox-treated double tg mice was emphasized by demon-
strating that blocking neutrophil accumulation within the CNS via
anti-CXCR2 treatment dramatically reduced demyelination. Previ-
ous studies from our laboratory [30, 32] and others [9, 47, 55, 56]
have demonstrated that administration of anti-CXCR2 blocking
antibody limits neutrophil mobilization from the bone marrow
and limits migration to the CNS in various models of neurodegen-
eration. Our findings provide further evidence that neutrophils
augment neurologic disease and emphasize that therapies target-
ing neutrophil accumulation within the CNS may offer novel alter-
native therapies for treating neuroinflammatory diseases.
Materials and methods
Mice
pBI-CXCL1-rtTA double transgenic mice (developed on the
C57BL/6 background) were developed as previously described
[21]. In brief, pBI-CXCL1 transgenic mice were generated by the
University of California, Irvine transgenic mouse facility through
DNAmicroinjection of fertilized C56BL/6 eggs using the linearized
pBI-CXCL1 construct [57]. The five resulting founder transgenic
(tg) mice were mated toWT C57BL/6 mice to identify F1 offspring
containing the transgene. To generate double transgenic (tg)mice,
hemizygous pBI-CXCL1 transgenics were crossed to hemizygous
GFAP-rtTA*M2 mice (JAX), resulting in double transgenic mice
(pBI-CXCL1-rtTA), single tg (rtTA-GFAP or pBI-CXCL1) or WT.
Dox administration to double tg results in elevated CXCL1 trans-
gene expression within astrocytes corresponding with increased
CXCL1 protein and neutrophil accumulation whereas Dox treat-
ment of single tg had no effect on CXCL1 expression nor neutrophil
accumulation within the CNS [21].
MOG35–55 EAE immunization
For induction of EAE, experimental mice (aged 6–8 weeks old)
were injected subcutaneously in the flanks with 200 μL of 1 mM
MOG35–55 peptide (DNA/Peptide Synthesis Core Facility, Univer-
sity of Utah) emulsified with reconstituted complete Freund’s
adjuvant (Pierce Biotechnology, Waltham, MA, USA) containing
Mycobacterium tuberculosis H37 Ra (2 mg/mL) (Difco Laborato-
ries, Franklin Lakes, NJ, USA). Mice were injected intravenously
with 100 μL Bordetella pertussis toxin (Ptx) (List Biological Labo-
ratories Inc., Campbell, CA, USA) at 0.2 μg/mouse on days 0 and
2 following sensitization. Double and single transgenic animals
were injected with doxycycline (Dox) (50 mg/kg via i.p. injection)
starting at day 9 following EAE induction and continuing through
day 19 postimmunization (p.i.). Experimental mice injected with
MOG35–55 were scored daily for clinical signs through day 21 fol-
lowing immunization using previously described methods [58].
In brief, 0, normal mouse with no signs of disease; 1, limp tail or
hind-limb weakness; 2, limp tail and hind-limb weakness; 3, par-
tial hind-limb paralysis; 4, complete hind-limb paralysis; 5, mori-
bund state/death. All animal experiments were approved by the
University of Utah Institutional Animal Care and Use Committee
protocol 18–01005.
Flow cytometry
Inflammatory leukocytes infiltrating into the CNS were isolated
using an established protocol (3,4). In short, CNS tissue was
C© 2018 The Authors. European Journal of Immunology published by
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minced and leukocytes were isolated using a two-step Percoll
gradient (90% and 63%). The isolated cells were collected and
then washed prior to staining. Cells were incubated in an anti-
CD16/32 Fc Block (BD Biosciences, San Jose, CA) at a dilution of
1:200. Cells were stained with fluorescently tagged rat anti-mouse
IgG for the following cell surface antibodies, Ly6G FITC (1A8),
CD11b PE (M1/70), CD45 BV510 (30-F11), CD8 PE-Cy7 (53–
6.7), (BD Biosciences), Ly6C APC (HK1.4), CD4 BV785 (RM4-5),
F4/80 FITC (BM8), I-A/I-E APC (M5/114.15.2), CD11c FITC
(N418) (Biolegend, San Diego, CA), and CD4 FITC (RM4-5) or
Armenian hamster anti-mouse IgG for CD80 PerCP-Cy5.5 (16-
10A1) (BD Biosciences). A full description of gating strategies for
flow cytometric staining and intracellular cytokine staining is pro-
vided in the Supporting Information Figs. S1–S4.
Ex vivo peptide restimulation
Spinal Isolated spinal cord leukocytes that were isolated using a
Percoll gradient as above, were stimulated with MOG35–55 peptide
or 50 ng/mL PMA (Sigma, St. Louis, MO) with 2 ug/mL Iono-
mycin (Sigma, St. Louis, MO) and BD Cytofix/Cytoperm Plus Fix-
ation/Permeabilization Kit (with BD GolgiPlug protein transport
inhibitor containing brefeldin A) (BD Biosciences, San Jose, CA)
and incubated at 37°C for 6 hours or 5 hours, respectively. Cells
were stained the surface marker CD4 (eBiosciences, San Diego,
CA) and for intracellular cytokines including Rat anti-mouse IgG,
IL-17A (eBiosciences, San Diego, CA) and IFN-γ (BD Biosciences).
Quantitative real-time PCR
Total cDNA from brains and spinal cords of sham and EAE immu-
nized mice at day 12 following disease induction was generated
via Superscript III (Life Tech., Carlsbad, CA) following homoge-
nization in Trizol (Life Tech., Carlsbad, CA).
Expression of mRNA from defined mouse chemokine and
cytokine genes including Cxcl1, Cxcl2, Cxcl10, Ccl2, Ccl5, IFN-γ,
and IL-17A within the brain of experimental mice was determined
by qPCR using SYBR Green I Master (Roche) on a LightCycler 480
(Roche) and normalized to β-actin [59].
Histology
Mice were euthanized according to IACUC guidelines and spinal
cords were removed, fixed overnight in 4% paraformaldehyde
(PFA) at 4°C and separated into eight 1.5 mm sections. Each
section was cryoprotected in 30% sucrose for five days before
embedding in OCT; 8 μM thick coronal sections were cut and
stained with luxol fast blue (LFB) combined with H&E. Pathol-
ogy scoring of spinal cord sections was performed using previ-
ously describedmethods; a minimum number of three mice/group
with 6–8 section/mouse assessed [60]. In brief, for scoring of
spinal cord section, each spinal cord section was divided into four
quadrants (the ventral funiculus, the dorsal funiculus, and each
lateral funiculus) [60]; any quadrant containing demyelination,
meningeal infiltration, or perivascular cuffing was given a score of
1 in that pathological class. The total number of positive quadrants
for each pathological class was determined and then divided by
the total number of quadrants present on the slide and multiplied
by 100 to give the percent involvement for each pathological class.
Immunofluorescence
Spinal cord sections were processed as described above. For
immunofluorescence, slides were first desiccated for two hours
and blocked with 5% Normal Donkey Serum with or without
0.3% Triton-X 100. Primary antibodies were incubated overnight
at 4°C: goat anti-CXCL1 1:50 (R&D Systems, Minneapolis, MN),
rabbit anti-GFAP 1:500 (Life Technologies, Carlsbad, CA), and
rat anti-Ly6B.2 1:100 (Serotec, Raleigh, NC). Images were ana-
lyzed using the Image J software (NIH) according to previously
describedmethods [61, 62]. Quantification of Ly6B.2-positive cells
within spinal cords of experimentalmicewas determined by count-
ing cells in a minimum of five spinal cord sections/per mouse with
a minimum of three mice per group.
Antibody administration
Rabbit polyclonal antiserum was generated to a 17-amino acid
portion of the amino-terminus ligand-binding domain of specific
for mouse CXCR2 (MGEFKVDKFNIEDFFSG) (Cocalico Biologicals,
Inc., Stevens, PA) and used to target neutrophils as previously
described has been previously described [9, 32, 55]. Normal rabbit
serum (NRS) from preimmunized rabbits was used as controls.
Experimental mice were injected i.p. with 0.5 mL with either anti-
CXCR2 or NRS every 2–3 days starting on day 9 following EAE
induction and ending on or before day 19.
Statistical analysis
Flow cytometric data were analyzed with FlowJo (Tree Star Inc.)
and an unpaired Student’s t-test was used, with a p < 0.05 being
considered as significant.
Acknowledgments: This work was funded by the National
Institutes of Health (NIH) R01NS041249 (T.E.L.) and NIH
R01NS091939 (T.E.L. and R.S.F.) and National Multiple Scle-
rosis Society (NMSS) CA-1607-25040 (T.E.L.). T.E.L. was also
supported by the Ray and Tye Noorda Foundation. B.S.M. was
supported by NIH Training Grant 5T3232A1007319. We appreci-
ate the excellent technical assistance of Sarah Winn.
C© 2018 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
Eur. J. Immunol. 2018. 48: 1199–1210 Immunodeficiencies and autoimmunity 1209
Conflict of interest: The authors declare no commercial or finan-
cial conflict of interest.
References
1 Baker, D. and Amor, S., Experimental autoimmune encephalomyelitis is
a good model of multiple sclerosis if used wisely.Mult. Scler. Relat. Disord.
2014. 3: 555–564.
2 Martin, R., McFarland, H. F. and McFarlin, D. E., Immunological aspects
of demyelinating diseases. Annu. Rev. Immunol. 1992. 10: 153–187.
3 Rao, P. and Segal, B. M., Experimental autoimmune encephalomyelitis.
Methods Mol. Biol. 2012. 900: 363–380.
4 Huseby, E. S., Liggitt, D., Brabb, T., Schnabel, B.,Ohlen, C. andGoverman,
J., A pathogenic role for myelin-specific CD8(+) T cells in a model for
multiple sclerosis. J. Exp. Med. 2001. 194: 669–676.
5 Zamvil, S., Nelson, P., Trotter, J., Mitchell, D., Knobler, R., Fritz, R.
and Steinman, L., T-cell clones specific for myelin basic protein induce
chronic relapsing paralysis and demyelination.Nature 1985. 317: 355–358.
6 Zamvil, S. S.,Mitchell, D. J.,Moore, A. C., Kitamura, K., Steinman, L. and
Rothbard, J. B., T-cell epitope of the autoantigen myelin basic protein
that induces encephalomyelitis. Nature 1986. 324: 258–260.
7 Frohman, T. C., Beh, S. C., Kildebeck, E. J., Narayan, R., Treadaway, K.,
Greenberg, B. and Frohman, E. M., Neurotherapeutic strategies for mul-
tiple sclerosis. Neurol. Clin. 2016. 34: 483–523.
8 Kroenke, M. A., Carlson, T. J., Andjelkovic, A. V. and Segal, B. M., IL-
12- and IL-23-modulated T cells induce distinct types of EAE based on
histology, CNS chemokine profile, and response to cytokine inhibition. J.
Exp. Med. 2008. 205: 1535–1541.
9 Carlson, T., Kroenke, M., Rao, P., Lane, T. E. and Segal, B., The Th17-
ELR+CXC chemokine pathway is essential for the development of central
nervous system autoimmune disease. J. Exp. Med. 2008. 205: 811–823.
10 Naegele, M., Tillack, K., Reinhardt, S., Schippling, S., Martin, R. and
Sospedra, M., Neutrophils in multiple sclerosis are characterized by a
primed phenotype. J. Neuroimmunol. 2012. 242: 60–71.
11 Pierson, E. R., Wagner, C. A. and Goverman, J. M., The contribution of
neutrophils to CNS autoimmunity. Clin. Immunol. 2018. 189: 23–28.
12 Rumble, J. M., Huber, A. K., Krishnamoorthy, G., Srinivasan, A., Giles, D.
A., Zhang, X., Wang, L. et al., Neutrophil-related factors as biomarkers
in EAE and MS. J. Exp. Med. 2015. 212: 23–35.
13 Simmons, S. B., Liggitt, D. and Goverman, J. M., Cytokine-regulated neu-
trophil recruitment is required for brain but not spinal cord inflammation
during experimental autoimmune encephalomyelitis. J. Immunol. 2014.
193: 555–563.
14 Aube, B., Levesque, S. A., Pare, A., Chamma, E., Kebir, H., Gorina, R.,
Lecuyer, M. A. et al., Neutrophils mediate blood-spinal cord barrier dis-
ruption in demyelinating neuroinflammatory diseases. J. Immunol. 2014.
193: 2438–2454.
15 Christy, A. L., Walker, M. E., Hessner, M. J. and Brown, M. A., Mast
cell activation and neutrophil recruitment promotes early and robust
inflammation in the meninges in EAE. J. Autoimmun. 2013. 42: 50–61.
16 Levesque, S. A., Pare, A., Mailhot, B., Bellver-Landete, V., Kebir, H.,
Lecuyer, M. A., Alvarez, J. I. et al., Myeloid cell transmigration across
the CNS vasculature triggers IL-1beta-driven neuroinflammation during
autoimmune encephalomyelitis in mice. J. Exp. Med. 2016. 213: 929–949.
17 Liu, Y., Holdbrooks, A. T., Meares, G. P., Buckley, J. A., Benveniste, E.
N. and Qin, H., Preferential recruitment of neutrophils into the cere-
bellum and brainstem contributes to the atypical experimental autoim-
mune encephalomyelitis phenotype. J. Immunol. 2015. 195: 841–852.
18 Miller, N. M., Wang, J., Tan, Y. and Dittel, B. N., Anti-inflammatory
mechanisms of IFN-gamma studied in experimental autoimmune
encephalomyelitis reveal neutrophils as a potential target in multiple
sclerosis. Front. Neurosci. 2015. 9: 287.
19 Stoolman, J. S., Duncker, P. C., Huber, A. K. and Segal, B. M., Site-specific
chemokine expression regulates central nervous system inflammation
and determines clinical phenotype in autoimmune encephalomyelitis. J.
Immunol. 2014. 193: 564–570.
20 Wu, F., Cao,W.,Yang, Y. and Liu, A., Extensive infiltration of neutrophils
in the acute phase of experimental autoimmune encephalomyelitis in
C57BL/6 mice. Histochem. Cell Biol. 2010. 133: 313–322.
21 Marro, B. S., Grist, J. J. and Lane, T. E., Inducible expression of CXCL1
within the central nervous system amplifies viral-induced demyelina-
tion. J. Immunol. 2016. 196: 1855–1864.
22 Kerstetter, A. E., Padovani-Claudio, D. A., Bai, L. and Miller, R. H., Inhi-
bition of CXCR2 signaling promotes recovery in models of multiple scle-
rosis. Exp. Neurol. 2009. 220: 44–56.
23 Liu, L., Darnall, L., Hu, T., Choi, K., Lane, T. E. and Ransohoff, R. M.,
Myelin repair is accelerated by inactivating CXCR2 on nonhematopoietic
cells. J. Neurosci. 2010. 30: 9074–9083.
24 Roy, M., Richard, J. F., Dumas, A. and Vallieres, L., CXCL1 can be reg-
ulated by IL-6 and promotes granulocyte adhesion to brain capillaries
during bacterial toxin exposure and encephalomyelitis. J. Neuroinflam-
mation 2012. 9: 18.
25 Wu, F., Zhao, Y., Jiao, T., Shi, D., Zhu, X., Zhang, M., Shi, M. et al., CXCR2
is essential for cerebral endothelial activation and leukocyte recruitment
during neuroinflammation. J. Neuroinflammation 2015. 12: 98.
26 Omari, K. M., John, G., Lango, R. and Raine, C. S., Role for CXCR2 and
CXCL1 on glia in multiple sclerosis. Glia 2006. 53: 24–31.
27 Luo, Y., Fischer, F. R., Hancock, W. W. and Dorf, M. E., Macrophage
inflammatory protein-2 and KC induce chemokine production by mouse
astrocytes. J. Immunol. 2000. 165: 4015–4023.
28 Glabinski, A. R., Tani, M., Strieter, R. M., Tuohy, V. K. and Ransohoff,
R. M., Synchronous synthesis of alpha- and beta-chemokines by cells
of diverse lineage in the central nervous system of mice with relapses
of chronic experimental autoimmune encephalomyelitis. Am. J. Pathol.
1997. 150: 617–630.
29 Lane, T. E.,Asensio, V. C.,Yu, N., Paoletti, A. D.,Campbell, I. L. and Buch-
meier, M. J., Dynamic regulation of alpha- and beta-chemokine expres-
sion in the central nervous system duringmouse hepatitis virus-induced
demyelinating disease. J. Immunol. 1998. 160: 970–978.
30 Hosking, M. P., Tirotta, E., Ransohoff, R. M. and Lane, T. E., CXCR2 sig-
naling protects oligodendrocytes and restricts demyelination in a mouse
model of viral-induced demyelination. PLoS One 2010. 5: e11340.
31 Segal, B. M., Th17 cells in autoimmune demyelinating disease. Semin.
Immunopathol. 32: 71–77.
32 Hosking, M. P., Liu, L., Ransohoff, R. M. and Lane, T. E., A protective role
for ELR+ chemokines during acute viral encephalomyelitis. PLoS Pathog.
2009. 5: e1000648.
33 Compston, A. and Coles, A., Multiple sclerosis. Lancet 2008. 372: 1502–
1517.
34 Hemmer, B., Nessler, S., Zhou, D., Kieseier, B. and Hartung, H. P.,
Immunopathogenesis and immunotherapy of multiple sclerosis. Nat.
Clin. Pract. Neurol. 2006. 2: 201–211.
35 Ransohoff, R. M., Hafler, D. A. and Lucchinetti, C. F., Multiple sclerosis-a
quiet revolution. Nat. Rev. Neurol. 2015. 11: 134–142.
C© 2018 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
1210 Jonathan J. Grist et al. Eur. J. Immunol. 2018. 48: 1199–1210
36 Sadik, C. D., Kim, N. D. and Luster, A. D., Neutrophils cascading their
way to inflammation. Trends Immunol. 2011. 32: 452–460.
37 Perobelli, S. M.,Galvani, R. G.,Goncalves-Silva, T., Xavier, C. R.,Nobrega,
A. and Bonomo, A., Plasticity of neutrophils revealsmodulatory capacity.
Braz. J. Med. Biol. Res. 2015. 48: 665–675.
38 Nathan, C., Neutrophils and immunity: challenges and opportunities.
Nat. Rev. Immunol. 2006. 6: 173–182.
39 Mantovani, A., Cassatella, M. A., Costantini, C. and Jaillon, S., Neu-
trophils in the activation and regulation of innate and adaptive immu-
nity. Nat. Rev. Immunol. 2011. 11: 519–531.
40 Casserly, C. S., Nantes, J. C., Whittaker Hawkins, R. F. and Vallieres, L.,
Neutrophil perversion in demyelinating autoimmune diseases: mecha-
nisms to medicine. Autoimmun. Rev. 2017. 16: 294–307.
41 Summers, C., Rankin, S. M., Condliffe, A. M., Singh, N., Peters, A. M. and
Chilvers, E. R., Neutrophil kinetics in health and disease. Trends Immunol.
2010. 31: 318–324.
42 Hosking, M. P. and Lane, T. E., ELR(+) chemokine signaling in host
defense and disease in a viral model of central nervous system disease.
Front Cell Neurosci. 2014. 8: 165.
43 Tani, M., Fuentes, M. E., Peterson, J. W., Trapp, B. D., Durham, S. K., Loy,
J. K., Bravo, R. et al., Neutrophil infiltration, glial reaction, and neuro-
logical disease in transgenic mice expressing the chemokine N51/KC in
oligodendrocytes. J. Clin. Invest. 1996. 98: 529–539.
44 Omari, K. M., Lutz, S. E., Santambrogio, L., Lira, S. A. and Raine, C. S.,
Neuroprotection and remyelination after autoimmune demyelination in
mice that inducibly overexpress CXCL1. Am. J. Pathol. 2009. 174: 164–
176.
45 Tirotta, E., Ransohoff, R. M. and Lane, T. E., CXCR2 signaling protects
oligodendrocyte progenitor cells from IFN-gamma/CXCL10-mediated
apoptosis. Glia 2011. 59: 1518–1528.
46 King, I. L., Dickendesher, T. L. and Segal, B. M., Circulating Ly-6C+
myeloid precursors migrate to the CNS and play a pathogenic role during
autoimmune demyelinating disease. Blood 2009. 113: 3190–3197.
47 Herz, J., Sabellek, P., Lane, T. E., Gunzer, M.,Hermann, D. M. and Doepp-
ner, T. R., Role of neutrophils in exacerbation of brain injury after focal
cerebral ischemia in hyperlipidemic mice. Stroke 2015. 46: 2916–2925.
48 Chen, H., Song, Y. S. and Chan, P. H., Inhibition of NADPH oxidase is
neuroprotective after ischemia-reperfusion. J. Cereb. Blood Flow Metab.
2009. 29: 1262–1272.
49 Hampton,M. B.,Kettle, A. J. andWinterbourn, C. C., Inside the neutrophil
phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 1998.
92: 3007–3017.
50 Weiss, S. J., Tissue destruction by neutrophils. N. Engl. J. Med. 1989. 320:
365–376.
51 Lucchinetti, C. F., Mandler, R. N., McGavern, D., Bruck, W., Gleich, G.,
Ransohoff, R. M., Trebst, C. et al., A role for humoral mechanisms in
the pathogenesis of Devic’s neuromyelitis optica. Brain 2002. 125: 1450–
1461.
52 Zhang, H., Bennett, J. L. and Verkman, A. S., Ex vivo spinal cord slice
model of neuromyelitis optica reveals novel immunopathogenic mecha-
nisms. Ann. Neurol. 2011. 70: 943–954.
53 Saadoun, S., Waters, P., MacDonald, C., Bell, B. A., Vincent, A., Verk-
man, A. S. and Papadopoulos, M. C., Neutrophil protease inhibition
reduces neuromyelitis optica-immunoglobulin G-induced damage in
mouse brain. Ann. Neurol. 2012. 71: 323–333.
54 Steinbach, K., Piedavent, M., Bauer, S., Neumann, J. T. and Friese, M. A.,
Neutrophils amplify autoimmune central nervous system infiltrates by
maturing local APCs. J. Immunol. 2013. 191: 4531–4539.
55 Liu, L., Belkadi, A., Darnall, L., Hu, T., Drescher, C., Cotleur, A. C.,
Padovani-Claudio, D. et al., CXCR2-positive neutrophils are essential for
cuprizone-induced demyelination: relevance to multiple sclerosis. Nat.
Neurosci. 2010. 13: 319–326.
56 Kohler, A., De Filippo, K., Hasenberg, M., van den Brandt, C., Nye, E.,
Hosking, M. P., Lane, T. E. et al., G-CSF-mediated thrombopoietin release
triggers neutrophil motility and mobilization from bone marrow via
induction of Cxcr2 ligands. Blood 2011. 117: 4349–4357.
57 Yu, J., Zhang, L.,Hwang, P. M., Rago, C., Kinzler, K.W. and Vogelstein, B.,
Identification and classification of p53-regulated genes. Proc. Natl. Acad.
Sci. USA 1999. 96: 14517–14522.
58 Cusick, M. F., Libbey, J. E., Oh, L., Jordan, S. and Fujinami, R. S., Acthar
gel treatment suppresses acute exacerbations in a murine model of
relapsing-remitting multiple sclerosis. Autoimmunity 2015. 48: 222–230.
59 Tirotta, E., Duncker, P., Oak, J., Klaus, S., Tsukamoto, M. R., Gov, L.
and Lane, T. E., Epstein-Barr virus-induced gene 3 negatively regulates
neuroinflammation and T cell activation following coronavirus-induced
encephalomyelitis. J. Neuroimmunol. 2013. 254: 110–116.
60 Sato, F.,Martinez, N. E., Shahid, M., Rose, J. W., Carlson, N. G. and Tsun-
oda, I., Resveratrol exacerbates both autoimmune and viral models of
multiple sclerosis. Am. J. Pathol. 2013. 183: 1390–1396.
61 Chen, L., Coleman, R., Leang, R., Tran, H., Kopf, A., Walsh, C. M., Sears-
Kraxberger, I. et al., Human neural precursor cells promote neurologic
recovery in a viral model of multiple sclerosis. Stem Cell Rep. 2014. 2:
825–837.
62 Blanc, C. A., Grist, J. J., Rosen, H., Sears-Kraxberger, I., Steward, O. and
Lane, T. E., Sphingosine-1-phosphate receptor antagonism enhances
proliferation and migration of engrafted neural progenitor cells in a
model of viral-induced demyelination.Am. J. Pathol. 2015. 185: 2819–2832.
Abbreviations: Dox: doxycycline · GFAP: glial fibrillary acidic protein ·
JHMV: JHM strain of mouse hepatitis virus · rtTA: reverse tetracycline-
controlled trans activator
Full correspondence: Dr. Thomas E. Lane, Department of Pathology,
Division of Microbiology and Immunology, University of Utah, School
of Medicine, Salt Lake City, UT 84112, USA
e-mail: tom.lane@path.utah.edu
Current address: Brett S. Marro, Department of Immunology and
Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
Current address: Jonathan J. Grist, Infectious and Inflammatory Disease
Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla,
CA 92037, USA
Received: 4/12/2017
Revised: 17/2/2018
Accepted: 20/4/2018
Accepted article online: 26/4/2018
C© 2018 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
